In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Need help?

Read the Frequently Asked Questions for a better use

Read more

 

Refine your search
Sponsor

ESC Congress 365

All ESC Congress resources in one online library

View thousands of videos, slides, abstracts and reports from the world's largest cardiovascular congress – anytime!

Any question or suggestion? Check the Frequently Asked Questions or send it to us by email.

 

 

ESC Congress 365 only features abstracts, slides, reports and/or videos for which the speakers and/or presenters have granted the European Society of Cardiology the rights to use for educational purposes.

presentations found.

SPONSORED RESOURCES

Presentations below are part of sessions supported by Bayer.

Bayer
Abstract Slides/e-posters Video Report ESC TV Interview
 
Oral anticoagulation in patients undergoing cardioversion: new horizons open up.
Presenter: M D Ezekowitz (Villanova,US)
2014
more
 
Questions - From acute PE to CTEPH: related diseases, different solutions.
Presenter: M Delcroix (Leuven,BE), H A Ghofrani (Giessen,DE), S V Konstantinides (Mainz,DE), A Torbicki (Otwock,PL)
2014
more
 
more
 
Panel discussion and audience Q&A - Perception or reality? Time to re-evaluate the safety of aspirin.
2014
more
 
Practical issues for use of oral factor Xa inhibition following ACS: risk stratification, patient selection,timing of therapy, bleeding risk reduction, stented patients and long-term management.
Presenter: P G Steg (Paris,FR)
2014
more
 
Discussion: should we screen all PE patients for CTEPH? Cons.
Presenter: A Torbicki (Otwock,PL)
2014
more
 
Discussion: should we screen all PE patients for CTEPH? Pros.
Presenter: M Delcroix (Leuven,BE)
2014
more
 
The evidence-based role for factor Xa-mediated cardioprotection following ACS: trial-based rationale for deploying factor Xa inhibition as part of mulitmodal post-ACS management.
Presenter: J Mega (Boston,US)
2014
more
 
What happens after acute PE? Insights into the transition to CTEPH.
Presenter: S V Konstantinides (Mainz,DE)
2014
more
 
Chairperson's welcome and introduction - Rivaroxaban in cardiology.
Presenter: E Peterson (Durham,US)
2014
more

The scientific programme has been prepared by the Congress Programme Committee in close collaboration with the ESC Working Groups, ESC Associations and the ESC Councils.

 

Bayer HealthCare